Business:
Pfizer to acquire drug company Medivation for $14 billion

Pfizer is buying the cancer drug company Medivation in a deal valued at about $14 billion.

Pfizer Inc. will pay $81.50 per Medivation share. That's a 21 percent premium to the San Francisco biotech's Friday closing price of $67.19.

Medivation Inc.'s stock soared more than 19 percent before the opening bell Monday.

The boards of both companies have approved the deal, which is targeted to close in the third of fourth quarter.

The Times will update this article

Source:   latimes
Source Link:   latimes

Misafir Avatar
Name
Submit Comment
Characters Left:
Your comment has been forwarded to the administrator for approval.×

Ashley Furniture slashes production in Inland...
The company says the majority of production at the site east of Los Angeles is going to other U.S. plants to create...

Read News